A preparation method of 5α-androsterone-17-hydroxy-3-ketone

By adopting the new process route of 3-androthenone ketone etherification, catalytic hydrogenation and 17-position ketone reduction of 4-androthenone, the problems of high production costs and serious environmental pollution in the existing technology are solved, and the process is realized Simplify and improve product purity, suitable for industrial production.

CN110563787BActive Publication Date: 2024-12-03HUAZHONG PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201910904656.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-24
Publication Date
2024-12-03
Estimated Expiration
2039-09-24

AI Technical Summary

Technical Problem

The existing preparation process of 5α-androster-17-hydroxy-3-one has problems such as high production costs, serious environmental pollution and cumbersome process steps, especially the environmental pressure caused by chromium pollution and cyanide pollution, as well as the intermediate at high temperatures. The structure is prone to deformity during drying, affecting process stability.

Method used

5α-androst-17- is prepared by using 4-androstenedione as raw material, 3-position ketone etherification, 5-position olefinic hydrogenation, 17-position ketone reduction and 3-position olefinic ether hydrolysis Hydroxy-3-one avoids high-temperature drying and high-temperature dissolution steps of alcohol. Triethylamine reflux and one-scoop stew process are used to ensure the stability and efficient reaction of the intermediate.

Benefits of technology

The process steps are simplified, production costs are reduced, product purity and yield are improved, environmental pollution is avoided, suitable for industrial large-scale production, and the stability and efficient reaction of intermediates are ensured.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002212926060000011
    Figure BDA0002212926060000011
  • Figure BDA0002212926060000021
    Figure BDA0002212926060000021
  • Figure BDA0002212926060000022
    Figure BDA0002212926060000022
Patent Text Reader

Abstract

The invention relates to a method for preparing 5α-androstenedione, which specifically comprises the following steps: step 1: subjecting 4-androstenedione to an etherification reaction with triethyl orthoformate and anhydrous ethanol in the presence of an etherification catalyst to prepare a compound 3-ethoxy-3,5-androstadiene-17-ketone wet material; step 2: sequentially adding a protective reagent and 3-ethoxy-3,5-androstadiene-17-ketone wet material to a mixed solvent of methanol-dichloromethane, and then carrying out a catalytic hydrogenation reaction under the action of a palladium-carbon catalyst to obtain a solution of 3-ethoxy-3-androstene-17-ketone; and step 3: adding a metal borohydride to the solution of 3-ethoxy-3-androstene-17-ketone to carry out a reduction reaction, and after the reduction reaction is completed, adding an acid to carry out a hydrolysis reaction, and after the hydrolysis reaction is completed, removing the solvent, filtering, washing, drying, and refining to obtain 5α-androstene-17-hydroxy-3-ketone. The method of the invention has the advantages of short process route, easy control of production process, environmental friendliness, low production cost and suitability for industrial-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of pharmaceutical chemicals, and in particular to a method for preparing 5α-androsterone-17-hydroxy-3-ketone. Background Art

[0002] 5α-androst-17-hydroxy-3-one, molecular formula C 19 H 30 O 2 , molecular weight 290.44, its structural formula is:

[0003]

[0004] 5α-Androst-17-hydroxy-3-one is a key intermediate in the production of dozens of steroid hormone drugs such as methenolone, anadrol, drostanolone, mesterolone, flavonoids, and stanozolol, and has a wide range of market applications.

[0005] The existing process uses diosgenin as a raw material, and obtains diene through reactions such as ring opening, acylation, oxidation, hydrolysis, and elimination. The diene is subjected to reactions such as oximation, Beckmann rearrangement, acid hydrolysis, and alkaline hydrolysis to obtain dehydroepiandrosterone, and then catalytic hydrogenation to obtain epiandrosterone, and androstanedione is prepared through oxidation reaction, and then the target product is prepared through reactions such as etherification protection, reduction, and hydrolysis. This method has a long process, and not only has the disadvantages of high cost of raw materials such as diosgenin or diene, extremely low yield, and tight supply of raw materials, but also the oxidation reaction of diosgenin to prepare diene and the oxidation reaction of epiandrosterone to prepare androstanedione require the use of chromic anhydride, and the industrial wastewater generated in the oxidation process contains a large amount of Cr 6+ and Cr 3+ , among which Cr 6+ It is a highly toxic substance. Once a certain amount of this ingredient is ingested into the human body, it will cause cancer. These chromium ions harm the environment and bring great environmental pressure to the production of enterprises. Due to the reduction of the planting area of ​​medicinal plants (turmeric) and the national environmental protection policies and industry restrictions, the prices of saponins and dienes have continued to soar. The high prices of raw materials and the tight supply have caused a significant increase in the production cost and market price of 5α-androst-17-hydroxy-3-one, which has had a significant impact on the global market of downstream hormone drugs including methenolone, anadrol, drostanolone, mesterolone, flazobol, stanozolol, etc.

[0006] 4-Androstenedione (4AD for short), which is a key raw material for steroidal compounds like saponin and diene, is produced by microbial transformation of soybean oil byproducts, which is cheap and easily available. This raw material is in sufficient supply due to the large number of production companies. Its price is only about half of diene, and chromium pollution is avoided. The application of cheap and easy-to-purchase 4AD as a key raw material for steroid hormone drugs is gaining more and more attention.

[0007] CN107098944A uses 4AD as an alternative raw material, selectively protects the 17-position keto group with acetone cyanohydrin or sodium cyanide to obtain the key intermediate cyanohydrin, and then prepares it through steps such as ethylene glycol acetal, alkaline hydrolysis, alkali metal borohydride reduction, catalytic hydrogenation, and acid hydrolysis. The synthetic process route is as follows:

[0008]

[0009] The above process route uses 4-androstenedione obtained by microbial fermentation of sterols for preparation, which has great cost advantages, simple process routes, and sufficient supply of raw material 4-androstenedione. However, a large amount of cyanide-containing wastewater will be produced in the synthesis of the key intermediate cyanohydrin, and the cyanide ion concentration in the industrial wastewater is about 500-800ppm. Since cyanide-containing compounds have highly toxic characteristics, the cyanide-containing industrial wastewater formed must be strictly treated and can only be discharged after meeting the standards. According to national emission standards, the cyanide ion concentration in the discharged wastewater must not exceed 5ppm, which is very difficult to handle. The huge pressure of environmental protection treatment of enterprises restricts the application of this process route in industrial production.

[0010] CN106496297A also uses 4AD as an alternative raw material, but changes the process route to prepare the product through steps such as 3-keto-etherification protection, alkali metal borohydride reduction, catalytic hydrogenation, and acid hydrolysis. The synthetic process route is as follows:

[0011]

[0012] The above process route is prepared by four steps of 4AD raw material, which is protected by 3-keto group enetherization, reduced by alkali metal borohydride, catalytic hydrogenation of 5-ene bond, and acidolysis. The synthetic route does not pass through the cyano protection of the 17-keto group, thus avoiding the difficulty of discharging and treating highly toxic wastewater containing cyanide ions. However, compounds containing 3-keto group enetherization structures are unstable, sensitive to moisture, high temperature and acidic conditions, and easily hydrolyzed into enones. 3-Ethoxy-androst-3,5-diene-17-one and 3-ethoxy-androst-3,5-diene-17-ol containing 3-keto group enetherization structures in the above process route are both chemically active compounds. 3-Ethoxy-androst-3,5-diene-17-one and 3-ethoxy-androst-3,5-diene-17-ol are easy to undergo structural changes at higher temperatures (dried above 50°C).

[0013] CN106496297A adopts the method of adding pyridine or sodium carbonate to adjust the pH after the etherification reaction is completed, and drying at a temperature below 70°C to obtain 3-ethoxy-androsta-3,5-diene-17-one (etherified product); the etherified product is then reduced by metal borohydride, concentrated, precipitated, and dried to obtain a crude product of 3-ethoxy-androsta-3,5-diene-17-ol (reduced product); the crude reduced product is then refined by reflux decolorization in alcohol, alcohol is recovered at normal pressure, the temperature is lowered, and the reduced product is dried at a temperature below 70°C to obtain a refined product. In this process route, the solids of 3-ethoxy-androst-3,5-dien-17-one and 3-ethoxy-androst-3,5-dien-17-ol will undergo structural changes when stored for a long time at room temperature, and drying at a higher temperature will further accelerate the structural changes. The structural changes of these two compounds will be more rapid when they are dissolved in methanol and ethanol solutions; adding pyridine and sodium carbonate at the end of the etherification reaction is beneficial to maintaining the stability of the etherified product, but the addition of pyridine will inevitably cause pyridine residues in the intermediate product due to the high boiling point of pyridine, and pyridine is toxic to the subsequent catalytic hydrogenation catalyst palladium carbon, and usually there will be a certain amount of organic sulfide in pyridine, which has a greater effect on the catalytic activity of palladium carbon, and has an adverse effect on the catalytic hydrogenation reaction; since the etherification reaction system is in a paste state, if sodium carbonate is added directly as a solid, it is likely to cause unevenness in the system, and adding it in the form of sodium carbonate aqueous solution will introduce water that is difficult to dry into the system. The crude product of the reduction obtained by hydrolysis contains a large amount of water, which is also difficult to dry. The alcohol dissolution and decolorization and drying below 70°C used in the subsequent crude product refining will easily cause changes in the structure of the reduction. Summary of the invention

[0014] In order to overcome the above-mentioned deficiencies in the prior art, the present invention provides a method for preparing 5α-androsterone-17-hydroxy-3-one, which solves the problems of high production cost, serious environmental pollution, complicated process steps, and changes in intermediate structure caused by high drying temperature in the existing preparation of 5α-androsterone-17-hydroxy-3-one.

[0015] In order to achieve the above object, the present invention is implemented by the following technical solutions:

[0016] A method for preparing 5α-androstane-17-hydroxy-3-one, using 4-androstenedione (abbreviated as 4AD) as a raw material, performing 3-keto ene etherification, catalytic hydrogenation of the 5-ene bond, 17-keto reduction, and finally performing 3-ene ether hydrolysis to prepare the compound 5α-androstane-17-hydroxy-3-one, specifically comprising the following steps:

[0017] Step 1: etherification reaction is carried out on 4-androstenedione with triethyl orthoformate and anhydrous ethanol in the presence of an etherification catalyst, and the etherification reaction is completed and then post-treated to obtain 3-ethoxy-3,5-androstadien-17-one wet material;

[0018] Step 2: adding a protecting agent and a wet material of 3-ethoxy-3,5-androstadien-17-one to a mixed solvent of methanol-dichloromethane in sequence, and then performing a catalytic hydrogenation reaction under the action of a palladium-carbon catalyst. After the reaction is completed, filtering out the catalyst to obtain a solution of the compound 3-ethoxy-3-androstadien-17-one;

[0019] Step 3: adding a metal borohydride to the solution of 3-ethoxy-3-androstene-17-one for reduction reaction, adding an acid for hydrolysis reaction, removing the solvent, filtering, washing, drying and refining to obtain 5α-androstene-17-hydroxy-3-one;

[0020] Synthesis route:

[0021]

[0022] Furthermore, in step 1, the specific steps of post-treatment are: adding triethylamine to the product of the complete etherification reaction, heating and refluxing for 1 hour, cooling to below 0°C, and filtering to obtain the compound 3-ethoxy-3,5-androstadien-17-one wet material.

[0023] Furthermore, in step 1, the etherification catalyst is pyridine hydrochloride or pyridine hydrobromide, and the etherification reaction temperature is 30-50°C.

[0024] Furthermore, in step 1, the ratio of 4-androstenedione: triethyl orthoformate: anhydrous ethanol: etherification catalyst is 1W: 0.5V~1.0V: 0.9V~1.2V: 0.015W~0.020W, wherein W represents g and V represents ml.

[0025] Furthermore, in step 2, the volume ratio of methanol to dichloromethane in the methanol-dichloromethane mixed solvent is 1:0.2-0.25.

[0026] Furthermore, in step 2, the protecting agent is triethylamine, and the pH value after adding the protecting agent is in the range of 7.5 to 9.0.

[0027] Furthermore, in step 2, the catalytic hydrogenation reaction temperature is 25-40° C.; the ratio of 3-ethoxy-3,5-androstadien-17-one wet material: mixed solvent: palladium carbon catalyst is 1W: 25V-30V: 0.1W-0.3W, wherein W represents g and V represents ml.

[0028] Furthermore, in step 3, the metal borohydride used in the reduction reaction is sodium borohydride or potassium borohydride, and the acid used in the hydrolysis reaction is refined hydrochloric acid with a mass percentage concentration of ≥35% or a sulfuric acid aqueous solution with a mass percentage concentration of ≥10%.

[0029] Furthermore, in step 3, the mass ratio of 3-ethoxy-3-androstene-17-one solution to metal borohydride is 1:0.1-0.15.

[0030] Therefore, compared with the prior art, the beneficial effects of the present invention are:

[0031] (1) Using 4-androstenedione as a raw material, a new process of etherification, catalytic hydrogenation, reduction, and hydrolysis was used to prepare the compound 5α-androst-17-hydroxy-3-one. After the etherification reaction, no reduction reaction was performed, but a one-pot process of catalytic hydrogenation, reduction, and hydrolysis was directly adopted. The new process route reduces the steps of water precipitation drying and alcohol recrystallization in the preparation of 3-ethoxy-androst-3,5-diene-17-ol (reduced product), avoiding the process steps of high temperature drying and high temperature dissolution in alcohol, which are extremely difficult to control, which are the process steps of drying at a high temperature and dissolving at a high temperature in alcohol, which are very unstable in the state of high temperature dissolution of the reduced product;

[0032] (2) In the post-treatment of the etherification reaction, triethylamine is added for reflux and the intermediate drying step is removed, which not only ensures the stability of 3-ethoxy-3,5-androstadien-17-one (etherified product), but also avoids the toxicity to the catalyst of the subsequent catalytic hydrogenation. In addition, the etherified product drying step is removed to avoid the occurrence of intermediate structural changes due to high drying temperature;

[0033] (3) When performing catalytic hydrogenation, reduction, and hydrolysis reactions, a one-pot process is used. In a mixed solvent, a protective reagent is first added and then 3-ethoxy-3,5-androstadien-17-one (etherified product) is added for catalytic hydrogenation reaction; after the catalytic hydrogenation reaction is complete, the 3-ethoxy-3-androstadien-17-one solution obtained after filtering out the palladium carbon catalyst is first subjected to reduction reaction with a metal borohydride and then to hydrolysis reaction with an acid without separation of the discharge. This effectively ensures the yield level of the process route of the present invention;

[0034] (4) The process route of the present invention is short, the production process is easy to control, environmentally friendly, low in production cost, and suitable for industrial-scale production. The raw material 4-androstenedione is cheap and easily available, the total mass yield of the new process is more than 80%, and the product purity can reach more than 99.0%, which is higher than the purity standard (98.0%) of the prior art. DETAILED DESCRIPTION

[0035] Examples are shown to specifically illustrate certain embodiments of the present invention, and should not be construed as limiting the scope of the present invention. The disclosed content of the present invention can be improved from materials, methods and reaction conditions at the same time, and all these improvements should fall within the spirit and scope of the present invention.

[0036] Embodiment 1:

[0037] A method for preparing 5α-androsterone-17-hydroxy-3-one, comprising the following steps:

[0038] Step 1: Preparation of compound 3-ethoxy-androstane-3,5-diene-17-one: add 100g of 4-androstenedione, 60ml of triethyl orthoformate, and 100ml of anhydrous ethanol into a reaction bottle, stir for 30 minutes after addition, then add 2.0g of pyridine hydrobromide, heat to 35°C to 45°C and keep warm for 6 hours to carry out etherification reaction; after the reaction is completed, cool to below 5°C, add triethylamine dropwise to adjust the pH value to 7.0 to 7.5, heat and reflux for 1 hour after addition; cool to below 0°C, filter to obtain 107.8g of compound 3-ethoxy-androstane-3,5-diene-17-one wet material;

[0039] Step 2: Prepare a solution of 3-ethoxy-3-androstene-17-one: add 625 ml of methanol and 125 ml of dichloromethane to a reaction bottle, stir evenly, then drop triethylamine to adjust the pH value to 8.0-8.5, then add 25 g of the 3-ethoxy-androstene-3,5-diene-17-one wet material obtained in the previous step, stir for 30 minutes, add 5 g of palladium carbon with a palladium content of 2%, replace the air in the reaction bottle with hydrogen, and introduce hydrogen at 30° C.-35° C. for reaction for 10 hours; after the reaction is completed, replace the hydrogen in the reaction bottle with nitrogen, and filter to obtain a solution of 3-ethoxy-3-androstene-17-one;

[0040] Step 3: Preparation of compound 5α-androstane-17-hydroxy-3-one: Cool the solution of 3-ethoxy-3-androstene-17-one, add 2.5 g of potassium borohydride in portions at 10°C to 15°C, add potassium borohydride for 20 minutes to 30 minutes, and continue to react at 10°C to 15°C for 3 hours after addition. After the reduction reaction is completed, cool down, and add refined hydrochloric acid diluted with water with a mass percentage concentration of ≥35.0% to the reduction reaction solution at 5°C to 10°C to adjust the pH to 2 to 3. After addition, heat up and react at 20°C to 25°C for 2 hours. After the hydrolysis reaction is complete, the temperature is lowered to below 5°C, and a 5% by mass concentration of potassium hydroxide aqueous solution is added dropwise to adjust the pH value to 6.0-7.0. After the solvent is evaporated under reduced pressure, the temperature is lowered to below 5°C, 800 ml of pure water is slowly added, and the temperature is further lowered to below 5°C. After stirring for 30 minutes, the mixture is allowed to stand for more than 2 hours, filtered, washed with water, and dried to obtain a crude product of 5α-androsterone-17-hydroxy-3-one. The crude product is then crystallized with a mixed solvent of acetone and ethyl acetate to obtain 15.3 g of a fine product of 5α-androsterone-17-hydroxy-3-one with an HPLC purity of 99.2%.

[0041] Embodiment 2:

[0042] A method for preparing 5α-androsterone-17-hydroxy-3-one, comprising the following steps:

[0043] Step 1: Preparation of compound 3-ethoxy-androstane-3,5-diene-17-one: add 100g of 4-androstenedione, 50ml of triethyl orthoformate, and 120ml of anhydrous ethanol into a reaction bottle, stir for 30 minutes after addition, then add 1.5g of pyridine hydrobromide, heat to 40°C to 50°C and keep warm for 7 hours to carry out etherification reaction; after the reaction is completed, cool to below 5°C, add triethylamine dropwise to adjust the pH value to 7.0 to 7.5, heat and reflux for 1 hour after addition; cool to below 0°C, filter to obtain 108.1g of compound 3-ethoxy-androstane-3,5-diene-17-one wet material;

[0044] Step 2: preparing a solution of 3-ethoxy-3-androstene-17-one: adding 600 ml of methanol and 150 ml of dichloromethane to a reaction bottle, stirring evenly, and then dropping triethylamine to adjust the pH value to 8.5-9.0, and then adding 30 g of the 3-ethoxy-androstene-3,5-diene-17-one wet material obtained in the previous step, stirring for 30 minutes, adding 9 g of palladium carbon with a palladium content of 2%, replacing the air in the reaction bottle with hydrogen, and introducing hydrogen at 25° C. to 30° C. for reaction for 9 hours; after the reaction is completed, replacing the hydrogen in the reaction bottle with nitrogen, filtering to obtain a solution of 3-ethoxy-3-androstene-17-one;

[0045] Step 3: Preparation of compound 5α-androstane-17-hydroxy-3-one: Cool the solution of 3-ethoxy-3-androstene-17-one, add 4.5 g of potassium borohydride in portions at 10°C to 15°C, add potassium borohydride for 20 minutes to 30 minutes, and continue to react at 10°C to 15°C for 2 hours after addition. After the reduction reaction is completed, cool down, add refined hydrochloric acid with a mass percentage concentration of ≥35.0% to the reduction reaction solution at 5°C to 10°C to adjust the pH to 2 to 3. After the addition, heat up and react at 35°C to 40°C for 2 hours. After the hydrolysis reaction is complete, the temperature is lowered to below 5°C, and a 5% by mass concentration of sodium hydroxide aqueous solution is added dropwise to adjust the pH value to 6.0-7.0. After the solvent is evaporated under reduced pressure, the temperature is lowered to below 5°C, 800 ml of pure water is slowly added, and the temperature is further lowered to below 5°C. After stirring for 30 minutes, the mixture is allowed to stand for more than 2 hours, filtered, washed with water, and dried to obtain a crude product of 5α-androsterone-17-hydroxy-3-one. The crude product is then crystallized with a mixed solvent of acetone and ethyl acetate to obtain 18.8 g of a fine product of 5α-androsterone-17-hydroxy-3-one with an HPLC purity of 99.5%.

[0046] Embodiment 3:

[0047] A method for preparing 5α-androsterone-17-hydroxy-3-one, comprising the following steps:

[0048] Step 1: Preparation of compound 3-ethoxy-androstane-3,5-diene-17-one: add 100g of 4-androstenedione, 100ml of triethyl orthoformate, and 90ml of anhydrous ethanol into a reaction bottle, stir for 30 minutes after addition, then add 2g of pyridine hydrochloride, heat to 30°C to 40°C and keep warm for 9 hours to carry out etherification reaction; after the reaction is completed, cool to below 5°C, add triethylamine dropwise to adjust the pH value to 7.0 to 7.5, heat and reflux for 1 hour after addition; cool to below 0°C, filter to obtain 106.9g of compound 3-ethoxy-androstane-3,5-diene-17-one wet material;

[0049] Step 2: preparing a solution of 3-ethoxy-3-androstene-17-one: adding 625 ml of methanol and 125 ml of dichloromethane to a reaction bottle, stirring evenly, and then dropping triethylamine to adjust the pH value to 7.5-8.0, and then adding 25 g of the 3-ethoxy-androstene-3,5-diene-17-one wet material obtained in the previous step, stirring for 30 minutes, adding 2.5 g of palladium carbon with a palladium content of 2%, replacing the air in the reaction bottle with hydrogen, and introducing hydrogen at 35° C. to 45° C. for reaction for 12 hours; after the reaction is completed, replacing the hydrogen in the reaction bottle with nitrogen, filtering to obtain a solution of 3-ethoxy-3-androstene-17-one;

[0050] Step 3: Compound 5α-androstane-17-hydroxy-3-one: Cool the solution of 3-ethoxy-3-androstene-17-one, add 2.5 g of sodium borohydride in portions at 10°C to 15°C, add sodium potassium borohydride for 20 minutes to 30 minutes, and continue to react at 10°C to 15°C for 3 hours after addition. After the reduction reaction is completed, cool down, add sulfuric acid aqueous solution with a mass percentage concentration of ≥10% to the reduction reaction solution at 5°C to 10°C to adjust the pH to 2 to 3. After the addition, heat up and react at 30°C to 35°C for 3 hours. After the hydrolysis reaction is complete, the temperature is lowered to below 5°C, and a 5% by mass concentration of sodium hydroxide aqueous solution is added dropwise to adjust the pH value to 6.0-7.0. After the solvent is evaporated under reduced pressure, the temperature is lowered to below 5°C, 800 ml of pure water is slowly added, and the temperature is further lowered to below 5°C. After stirring for 30 minutes, the mixture is allowed to stand for more than 2 hours, filtered, washed with water, and dried to obtain a crude product of 5α-androsterone-17-hydroxy-3-one. The crude product is then crystallized with a mixed solvent of acetone and ethyl acetate to obtain 15.6 g of a fine product of 5α-androsterone-17-hydroxy-3-one with an HPLC purity of 99.3%.

[0051] The preparation method of the present application does not undergo a reduction reaction after the etherification reaction, but directly adopts a one-stop process of catalytic hydrogenation, reduction, and hydrolysis reactions. It has the advantages of a short process route, easy production process control, environmental friendliness, low production cost, and suitability for industrial-scale production.

[0052] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for preparing 5α-androsterone-17-hydroxy-3-one, characterized in that: The specific steps include: Step 1: etherification reaction is carried out on 4-androstenedione with triethyl orthoformate and anhydrous ethanol in the presence of an etherification catalyst, and the etherification reaction is completed and then post-treated to obtain 3-ethoxy-3,5-androstadien-17-one wet material; Step 2: adding a protecting agent and a wet material of 3-ethoxy-3,5-androstadien-17-one to a mixed solvent of methanol-dichloromethane in sequence, and then performing a catalytic hydrogenation reaction under the action of a palladium-carbon catalyst. After the reaction is completed, filtering out the catalyst to obtain a solution of the compound 3-ethoxy-3-androstadien-17-one; Step 3: adding a metal borohydride to the solution of 3-ethoxy-3-androstene-17-one for reduction reaction, adding an acid for hydrolysis reaction, removing the solvent, filtering, washing, drying and refining to obtain 5α-androstene-17-hydroxy-3-one; In step 1, the specific steps of post-treatment are: adding triethylamine to the product of the complete etherification reaction, heating and refluxing for 1 hour, cooling to below 0° C., and filtering to obtain a wet material of the compound 3-ethoxy-3,5-androstadien-17-one; In step 2, the protecting agent is triethylamine, and the pH value after adding the protecting agent is in the range of 7.5 to 9.0; the volume ratio of methanol to dichloromethane in the methanol-dichloromethane mixed solvent is 1:0.2 to 0.

25.

2. The method for preparing 5α-androsterone-17-hydroxy-3-one according to claim 1, characterized in that: In step 1, the etherification catalyst is pyridine hydrochloride or pyridine hydrobromide, and the etherification reaction temperature is 30-50°C.

3. The method for preparing 5α-androsterone-17-hydroxy-3-one according to claim 1, characterized in that: In step 1, the ratio of 4-androstenedione: triethyl orthoformate: anhydrous ethanol: etherification catalyst is 1W: 0.5V~1.0V: 0.9V~1.2V: 0.015W~0.020W, wherein W represents g and V represents ml.

4. The method for preparing 5α-androsterone-17-hydroxy-3-one according to claim 1, characterized in that: In step 2, the catalytic hydrogenation reaction temperature is 25-40° C.; the ratio of 3-ethoxy-3,5-androstadien-17-one wet material: mixed solvent: palladium carbon catalyst is 1W: 25V-30V: 0.1W-0.3W, wherein W represents g and V represents ml.

5. The method for preparing 5α-androsterone-17-hydroxy-3-one according to claim 1, characterized in that: In step 3, the metal borohydride used in the reduction reaction is sodium borohydride or potassium borohydride, and the acid used in the hydrolysis reaction is refined hydrochloric acid with a mass percentage concentration of ≥35% or a sulfuric acid aqueous solution with a mass percentage concentration of ≥10%.

6. The method for preparing 5α-androsterone-17-hydroxy-3-one according to claim 1, characterized in that: In step 3, the mass ratio of 3-ethoxy-3-androstene-17-one solution to metal borohydride is 1:0.1-0.15.